TY - JOUR
T1 - The Rebirth of Radioimmunotherapy of Non-Hodgkin Lymphoma
T2 - The Phoenix of Nuclear Medicine?
AU - Wahl, Richard L.
AU - Kahl, Brad
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/7
Y1 - 2024/7
N2 - In Greek mythology, The Phoenix is an immortal bird that dies, but then achieves new life by rising from the ashes of its predecessor. Radioimmunotherapy (RIT) of B-cell Non-Hodgkin lymphoma (NHL) is a field which once began to fly high—with FDA approval of the anti-CD20 RITs Zevalin® and Bexxar® in 2002 and 2003 respectively, as safe and effective therapies of NHL. However, despite their therapeutic efficacy, Bexxar® was withdrawn from the market by the manufacturer in 2014 due to limited commercial demand and Zevalin® has had very limited to no availability of late. I-131 rituximab is used to a limited extent in Australia, India and other countries, as well.
AB - In Greek mythology, The Phoenix is an immortal bird that dies, but then achieves new life by rising from the ashes of its predecessor. Radioimmunotherapy (RIT) of B-cell Non-Hodgkin lymphoma (NHL) is a field which once began to fly high—with FDA approval of the anti-CD20 RITs Zevalin® and Bexxar® in 2002 and 2003 respectively, as safe and effective therapies of NHL. However, despite their therapeutic efficacy, Bexxar® was withdrawn from the market by the manufacturer in 2014 due to limited commercial demand and Zevalin® has had very limited to no availability of late. I-131 rituximab is used to a limited extent in Australia, India and other countries, as well.
UR - http://www.scopus.com/inward/record.url?scp=85198737851&partnerID=8YFLogxK
U2 - 10.1053/j.semnuclmed.2024.06.002
DO - 10.1053/j.semnuclmed.2024.06.002
M3 - Review article
C2 - 39019652
AN - SCOPUS:85198737851
SN - 0001-2998
VL - 54
SP - 513
EP - 529
JO - Seminars in Nuclear Medicine
JF - Seminars in Nuclear Medicine
IS - 4
ER -